These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23443928)

  • 1. Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement.
    Pritchard KI; Gelmon KA; Rayson D; Provencher L; Webster M; McLeod D; Verma S
    Curr Oncol; 2013 Feb; 20(1):48-61. PubMed ID: 23443928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
    Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
    Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
    Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
    Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
    Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
    J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
    Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
    Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
    O'Shaughnessy J; Thaddeus Beck J; Royce M
    Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
    Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
    Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
    Baselga J; Campone M; Piccart M; Burris HA; Rugo HS; Sahmoud T; Noguchi S; Gnant M; Pritchard KI; Lebrun F; Beck JT; Ito Y; Yardley D; Deleu I; Perez A; Bachelot T; Vittori L; Xu Z; Mukhopadhyay P; Lebwohl D; Hortobagyi GN
    N Engl J Med; 2012 Feb; 366(6):520-9. PubMed ID: 22149876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
    Steger GG; Egle D; Bartsch R; Pfeiler G; Petru E; Greil R; Helfgott R; Marth C; Öhler L; Hubalek M; Lang A; Tinchon C; Haslbauer F; Redl A; Hock K; Hennebelle M; Mraz B; Gnant M
    Breast; 2020 Apr; 50():64-70. PubMed ID: 32062536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.
    Dhillon S
    Drugs; 2013 Apr; 73(5):475-85. PubMed ID: 23529824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
    Reinert T; Barrios CH
    Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
    Campone M; Bachelot T; Gnant M; Deleu I; Rugo HS; Pistilli B; Noguchi S; Shtivelband M; Pritchard KI; Provencher L; Burris HA; Hart L; Melichar B; Hortobagyi GN; Arena F; Baselga J; Panneerselvam A; Héniquez A; El-Hashimyt M; Taran T; Sahmoud T; Piccart M
    Eur J Cancer; 2013 Aug; 49(12):2621-32. PubMed ID: 23735704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
    Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
    JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Turner NC; Swift C; Kilburn L; Fribbens C; Beaney M; Garcia-Murillas I; Budzar AU; Robertson JFR; Gradishar W; Piccart M; Schiavon G; Bliss JM; Dowsett M; Johnston SRD; Chia SK
    Clin Cancer Res; 2020 Oct; 26(19):5172-5177. PubMed ID: 32546646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
    Nagaraj G; Ma CX
    Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exemestane: a review of its use in postmenopausal women with breast cancer.
    Deeks ED; Scott LJ
    Drugs; 2009; 69(7):889-918. PubMed ID: 19441873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.